Crinetics Pharmaceuticals (FRA:6Z4) Total Receivables: €4.92 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Z4 Crinetics Pharmaceuticals Inc FRA:6Z4
50 GF Score
Price €70.90
GF Value €626.58
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Total Receivables?

Crinetics Pharmaceuticals FRA:6Z4 -1.23% 50 Total Receivables is €4.92 Mil as of Mar. 2026. GuruFocus rates FRA:6Z4 with a GF Score™ of 50/100 and a GF Value™ of €626.58 (Possible Value Trap). The stock has 7 warning signs investors should review.

Crinetics Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was €4.92 Mil.

Crinetics Pharmaceuticals Total Receivables Related Terms

Crinetics Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Crinetics Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crinetics Pharmaceuticals Total Receivables Chart

Crinetics Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.80 2.86 8.58 0.00 0.51

Crinetics Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.77 0.00 0.00 0.51 4.92
FRA:6Z4
50GF Score
Crinetics Pharmaceuticals Inc FRA:6Z4
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crinetics Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €4.92 Mil mean?
Crinetics Pharmaceuticals (FRA:6Z4) has a Total Receivables of €4.92 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Crinetics Pharmaceuticals and its competitors.
Is Crinetics Pharmaceuticals' Total Receivables too high?
Crinetics Pharmaceuticals' current Total Receivables is €4.92 Mil. Overall, Crinetics Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Total Receivables compare to CPRX and NAMS?
Crinetics Pharmaceuticals' Total Receivables of €4.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Crinetics Pharmaceuticals and its competitors. Crinetics Pharmaceuticals's current Total Receivables is €4.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (FRA:6Z4) is currently considered Possible Value Trap. The stock's GF Value™ is €626.58, compared to a current price of €70.90 — trading 88.7% below its estimated fair value. The current Total Receivables is €4.92 Mil. Crinetics Pharmaceuticals' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Crinetics Pharmaceuticals (FRA:6Z4), the current Total Receivables is €4.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of €70.90 is trading 88.7% below its estimated GF Value™ of €626.58. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:6Z4:

  • Total Receivables: €4.92 Mil
  • GF Value™: €626.58 vs. price of €70.90 (88.7% below fair value)
  • GF Score™: 50/100 with 7 warning signs

No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges CRNX:USA
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
50GF Score

Get the complete analysis for FRA:6Z4

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.90
Price
€626.58
GF Value